Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hervé Tilly(Centre Virchow-Villermé), M. Dreyling(Ludwig-Maximilians-Universität München), María Gomes da Silva(Instituto Português de Oncologia Francisco Gentil), Umberto Vitolo(Candiolo Cancer Institute), Ofer Shpilberg(Texas Oncology), Marc André(CHU Dinant Godinne UCL Namur), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Pfreundschuh(Saarland University)
Cited by 172
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920